Contact
Newsroom
Skip to content
Patients
What is DVT
VTE Silent Killer
What is Circul8
Product How To Videos
Physicians
Orthopedic
OBGYN
Podiatry
Spine
DME
30 min protocol
Facilities
Surgery Center
Hospital
30 min protocol
Cost Savings
Products
About Us
Menu
Financial Perspectives in DVT Prophylaxis
Hospitals save a significant amount of money when they use a take home DVT prevention device. Circul8 is the only take home DVT prevention device available that incorporates Bluetooth technology and mobile device app for ease of use and patient monitoring.
The Clinical Studies Surrounding Financial Implications for DVT Prevention Methods
Venous thromboembolism (VTE) refers to the formation of blood clots within the veins of the body, most commonly the deep veins of the legs—deep vein thrombosis (DVT), and the complications that can happen when these clots break off into the circulation and get lodged in vessels elsewhere, most importantly in the pulmonary artery of the lungs. Pulmonary artery blockage can give rise to the life-threatening condition called pulmonary embolism (PE), which manifests as breathlessness, chest pain, and sudden death. The risk of developing VTE with major orthopedic surgery can be as high as 57%.
Acute VTE
Recurrent VTE
Post-thrombotic syndrome
Chronic pulmonary hypertension
Anticoagulation-related complications
Financial Perspectives in DVT Prophylaxis:
Newest generation tubeless cordless SCDs are most cost-effective.
1
Is
VTE prophylaxis
or
no prophylaxis
more cost-effective?
Evidence indicates that
VTE prophylaxis
is more cost-effective
2
Is
chemical
or
mechanical
prophylaxis more cost-effective?
Evidence indicates that
mechanical prophylaxis
is more cost-effective.
3
What
type of mechanical prophylaxis
is most cost-effective?
Newest generation
tubeless cordless SCDs
are most cost-effective.
Value analysis of Precision’s state-of-the-art Circul8 device
Cost savings on using prophylactic measures for VTE
VTE-related Per Patient
Readmission Costs
VTE-related
Incremental Cost
Per Patient
Cost Savings
with Prophylaxis
$11,862
$14,722
$2,663
Up to
$181
Result:
Mechanical Prophylaxis (IPCs)
more Cost-effective
Cost advantage per patient $369
Cost savings per 10,000-cohort $3.69 million
The ideal Prophylaxis should be:
Effective
Safe
Economical
The most cost-effective DVT prophylaxis: Circul8
Precision Medical Products provides a comprehensive DVT prevention program to hospitals, clinics, and ambulatory surgery centers. The program revolves around a state-of-the-art DVT prevention device—the Circul8. It is a mobile, battery-operated, tubeless, and cordless sequential compression device that is as safe as it is effective
Cumulative saving with a battery-operated SCD such as Circul8
is $550 per patient
REFERENCES
1. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):338S–400S
2. Grosse SD, Nelson RE, Nyarko KA, Richardson LC, Raskob GE. The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs. Thromb Res. 2016;137:3–10. doi:10.1016/j.thromres.2015.11.033
3. Bernatz JT, Tueting JL, Anderson PA. Thirty-day readmission rates in orthopedics: a systematic review and meta-analysis. PLoS One. 2015;10(4):e0123593. Published 2015 Apr 17. doi:10.1371/journal.pone.0123593
4. Bernatz JT, Tueting JL, Hetzel S, Anderson PA. What Are the 30-day Readmission Rates Across Orthopaedic Subspecialties?. Clin Orthop Relat Res. 2016;474(3):838–847. doi:10.1007/s11999-015-4602-5
5. Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: An administrative claims analysis from 30 managed care organizations. J Manag Care Pharm. 2007;13(6):475-86
6. Vekeman F, LaMori J, Laliberté F et al. Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population. J Med Econ. 2011;14(3):324-334. doi:10.3111/13696998.2011.578698
7. Vekeman F, LaMori J, Laliberté F et al. In-hospital risk of venous thromboembolism and bleeding and associated costs for patients undergoing total hip or knee arthroplasty. J Med Econ. 2012;15(4):644-653. doi:10.3111/13696998.2012.669438
8. Bozic KJ, Ward L, Vail TP, Maze M. Bundled payments in total joint arthroplasty: targeting opportunities for quality improvement and cost reduction. Clin Orthop Relat Res. 2014;472:188–193. doi: 10.1007/s11999-013-3034-3
9. Oster G. A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery. JAMA: The Journal of the American Medical Association. 1987;257(2):203-208. doi:10.1001/jama.257.2.203
10. Bergqvist D, Lindgren B, Mätzsch T. Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparin. Br J Surg. 1996; 83: 1548–1552
11. Torrejon Torres R, Saunders R, Ho K. A comparative cost-effectiveness analysis of mechanical and pharmacological VTE prophylaxis after lower limb arthroplasty in Australia. J Orthop Surg Res. 2019;14(1). doi:10.1186/s13018-019-1124-y
12. Saunders R, Comerota AJ, Ozols A, Torrejon Torres R, Ho KM. Intermittent pneumatic compression is a cost-effective method of orthopedic postsurgical venous thromboembolism prophylaxis. Clinicoecon Outcomes Res. 2018;10:231–241. Published 2018 Apr 19. doi:10.2147/CEOR.S157306
13. Cost-Effectiveness of Venous Thromboembolism Prophylaxis With a New Mobile Device After Total Hip Arthroplasty. J Arthroplasty. 2012;27(8):1513-1517.e1. doi:10.1016/j.arth.2012.03.024
14. Unexpected Risk from a Beneficial Device: Sequential Compression Devices and Patient Falls. PA PSRS Patient Saf Advis 2005 Sep;2(3):13-5
15. Johnston J, Davis M. When Sequential-Compression Devices Cause Falls. AJN, American Journal of Nursing. 2008;108(4):37-38. doi:10.1097/01.naj.0000315258.46329.34
16. Morello R, Barker A, Watts J et al. The extra resource burden of in-hospital falls: a cost of falls study. Med J Aust. 2015;203(9):367. doi:10.5694/mja15.00296
Patients
What is DVT
VTE Silent Killer
What is Circul8
Product How To Videos
Back
Physicians
Orthopedic
OBGYN
Podiatry
Spine
DME
30 min protocol
Back
Facilities
Surgery Center
Hospital
30 min protocol
Cost Savings
Back
Products
About Us